A potential antitumor ellagitannin, davidiin, inhibited hepatocellular tumor growth by targeting EZH2
A potential antitumor ellagitannin, davidiin, inhibited hepatocellular tumor growth by targeting EZH2
复制标题
DOI：
10.1007/s13277-013-1025-3
复制
发表时间：
2014-01-01
期刊：
影响因子：
--
通讯作者：
Chen, Yangchao
中科院分区：
文献类型：
--
作者：
Wang, Yan;Ma, Jingyi;Chen, Yangchao
肝细胞癌（HCC）是全球第五大常见癌症，也是癌症相关死亡的第三大常见原因。目前肝癌患者的治疗方案很少，迫切需要开发一种新的有效的治疗方法。头状蓼是一种草药，在中国苗族已被用于治疗炎症性疾病。我们最近从P. Capitatumextract.用Davidiin处理四种HCC细胞系。MTT法检测细胞活力。应用靶向zeste增强子同源物2（EZH2）的siRNA来调节EZH2的表达。建立小鼠肝癌移植瘤模型，评价Davidiin的体内抗肿瘤活性。我们研究了Davidin的抗癌活性及其潜在机制。该化合物抑制HCC细胞生长，并且还抑制异种移植HCC小鼠中的肿瘤生长。这种抑制通过特异性下调EZH2来促进。该化合物在体内外均具有抗癌活性，值得进一步的临床研究作为一种潜在的抗肝癌药物。
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and is the third most common cause of cancer-related deaths. Currently available treatment options for HCC patients are scarce resulting in an urgent need to develop a novel effective cure.Polygonum capitatumis a medicinal herb which has been used to treat inflammatory diseases in Miao nationality of China. We recently isolated a pure compound davidiin fromP. capitatumextract. Four HCC cell lines were treated with davidiin. Cell viability was recorded by MTT assay. siRNAs targeting enhancer of zeste homolog 2 (EZH2) were applied to modulate the expression of EZH2. Established xenograft mice models of HCC were applied to evaluate the in vivo anticancer activity of davidiin. We investigated the anticancer activity and the underlying mechanism of davidiin. The compound inhibited HCC cell growth and also suppressed tumor growth in xenografted HCC mouse. Such inhibition was facilitated by specifically downregulation on EZH2. The compound possesses anticancer activity both in vitro and in vivo which warrants further clinical investigation as a potential anti-HCC agent.